p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy
Abstract
:1. Introduction
2. Results
2.1. BCAR1 Is Strongly Expressed and Associated with Poor Survival in Colorectal Cancer
2.2. p130Cas Is Strongly Expressed and Phosphorylated and Drives Migration but Inhibits Proliferation in CRC Cell Lines
2.3. p130Cas/BCAR1 and EREG Expression Is Negatively Correlated in Colorectal Adenocarcinomas and CRC Cell Lines
2.4. The Negative Correlation of BCAR1 and EREG Expression Is More Pronounced in Right-Sided and Earlier Stages of Colorectal Adenocarcinomas
2.5. BCAR1 and EREG Expression Is Induced by Standard Chemotherapy and Upregulated in Distant Metastases
2.6. p130Cas Knockdown Sensitizes CRC Cells to FOLFIRI Independent of EREG Treatment
2.7. p130Cas Is Involved in Controlling Cytochrome P450 Drug Metabolism and Epithelial-Mesenchymal Transition (EMT) and MTORC Signaling Pathways
2.8. BCAR1 Expression Is Associated with Poor Outcome in Right-Sided, Stage I/II, MSS or BRAF-Mutated CRC
3. Discussion
4. Materials and Methods
4.1. Generation of Expression Constructs
4.2. Cell Lines and Transient Transfections
4.3. RNA Interference
4.4. Reverse Transcriptase (RT) qPCR Expression Analysis
4.5. Immunoblot (IB) Analysis
4.6. Migration Assay
4.7. Proliferation and Cell Viability Assay
4.8. Data Sources and Statistical Analyses
4.9. RNA Sequencing, Data Processing, and Analyses
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [Green Version]
- Shah, M.A.; Renfro, L.A.; Allegra, C.J.; Andre, T.; de Gramont, A.; Schmoll, H.J.; Haller, D.G.; Alberts, S.R.; Yothers, G.; Sargent, D.J. Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: Analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (accent) database. J. Clin. Oncol. 2016, 34, 843–853. [Google Scholar] [CrossRef] [PubMed]
- Parseghian, C.M.; Napolitano, S.; Loree, J.M.; Kopetz, S. Mechanisms of innate and acquired resistance to anti-egfr therapy: A review of current knowledge with a focus on rechallenge therapies. Clin. Cancer Res. 2019, 25, 6899–6908. [Google Scholar] [CrossRef] [PubMed]
- DeSantis, C.E.; Lin, C.C.; Mariotto, A.B.; Siegel, R.L.; Stein, K.D.; Kramer, J.L.; Alteri, R.; Robbins, A.S.; Jemal, A. Cancer treatment and survivorship statistics, 2014. CA Cancer J. Clin. 2014, 64, 252–271. [Google Scholar] [CrossRef]
- Fearon, E.R.; Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 1990, 61, 759–767. [Google Scholar] [CrossRef]
- Guinney, J.; Dienstmann, R.; Wang, X.; de Reynies, A.; Schlicker, A.; Soneson, C.; Marisa, L.; Roepman, P.; Nyamundanda, G.; Angelino, P.; et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 2015, 21, 1350–1356. [Google Scholar] [CrossRef] [PubMed]
- Stahler, A.; Heinemann, V.; Schuster, V.; Heinrich, K.; Kurreck, A.; Giessen-Jung, C.; Fischer von Weikersthal, L.; Kaiser, F.; Decker, T.; Held, S.; et al. Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (xelaviri trial). Eur. J. Cancer 2021, 157, 71–80. [Google Scholar] [CrossRef] [PubMed]
- Stintzing, S.; Wirapati, P.; Lenz, H.J.; Neureiter, D.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Kaiser, F.; Al-Batran, S.; Heintges, T.; et al. Consensus molecular subgroups (cms) of colorectal cancer (crc) and first-line efficacy of folfiri plus cetuximab or bevacizumab in the fire3 (aio krk-0306) trial. Ann. Oncol. 2019, 30, 1796–1803. [Google Scholar] [CrossRef] [Green Version]
- Lenz, H.J.; Ou, F.S.; Venook, A.P.; Hochster, H.S.; Niedzwiecki, D.; Goldberg, R.M.; Mayer, R.J.; Bertagnolli, M.M.; Blanke, C.D.; Zemla, T.; et al. Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: Results from calgb/swog 80405 (alliance). J. Clin. Oncol. 2019, 37, 1876–1885. [Google Scholar] [CrossRef] [PubMed]
- Stefani, C.; Miricescu, D.; Stanescu, S., II; Nica, R.I.; Greabu, M.; Totan, A.R.; Jinga, M. Growth factors, pi3k/akt/mtor and mapk signaling pathways in colorectal cancer pathogenesis: Where are we now? Int. J. Mol. Sci. 2021, 22, 10260. [Google Scholar] [CrossRef]
- Taank, Y.; Agnihotri, N. Understanding the regulation of beta-catenin expression and activity in colorectal cancer carcinogenesis: Beyond destruction complex. Clin. Transl. Oncol. 2021, 3, 2448–2459. [Google Scholar] [CrossRef] [PubMed]
- Tikhmyanova, N.; Little, J.L.; Golemis, E.A. Cas proteins in normal and pathological cell growth control. Cell. Mol. Life Sci. 2010, 67, 1025–1048. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nikonova, A.S.; Gaponova, A.V.; Kudinov, A.E.; Golemis, E.A. Cas proteins in health and disease: An update. IUBMB Life 2014, 66, 387–395. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kumbrink, J.; Kirsch, K.H. Targeting cas family proteins as a novel treatment for breast cancer. In Breast Cancer-Current and Alternative Therapeutic Modalities; Gunduz, E., Gunduz, M., Eds.; InTech: London, UK, 2011. [Google Scholar]
- Brinkman, A.; van der Flier, S.; Kok, E.M.; Dorssers, L.C. Bcar1, a human homologue of the adapter protein p130cas, and antiestrogen resistance in breast cancer cells. J. Natl. Cancer Inst. 2000, 92, 112–120. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sakai, R.; Iwamatsu, A.; Hirano, N.; Ogawa, S.; Tanaka, T.; Mano, H.; Yazaki, Y.; Hirai, H. A novel signaling molecule, p130, forms stable complexes in vivo with v-crk and v-src in a tyrosine phosphorylation-dependent manner. EMBO J. 1994, 13, 3748–3756. [Google Scholar] [CrossRef]
- Camacho Leal, M.D.P.; Costamagna, A.; Tassone, B.; Saoncella, S.; Simoni, M.; Natalini, D.; Dadone, A.; Sciortino, M.; Turco, E.; Defilippi, P.; et al. Conditional ablation of p130cas/bcar1 adaptor protein impairs epidermal homeostasis by altering cell adhesion and differentiation. Cell Commun. Signal. 2018, 16, 73. [Google Scholar] [CrossRef] [Green Version]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [Green Version]
- Heumann, A.; Heinemann, N.; Hube-Magg, C.; Lang, D.S.; Grupp, K.; Kluth, M.; Minner, S.; Moller-Koop, C.; Graefen, M.; Heinzer, H.; et al. High bcar1 expression is associated with early psa recurrence in erg negative prostate cancer. BMC Cancer 2018, 18, 37. [Google Scholar] [CrossRef]
- Mao, C.G.; Jiang, S.S.; Wang, X.Y.; Tao, S.L.; Jiang, B.; Mao, C.Y.; Yang, Y.L.; Hu, Z.Y.; Long, T.; Jin, H.; et al. Bcar1 plays critical roles in the formation and immunoevasion of invasive circulating tumor cells in lung adenocarcinoma. Int. J. Biol. Sci. 2021, 17, 2461–2475. [Google Scholar] [CrossRef] [PubMed]
- Waters, A.M.; Khatib, T.O.; Papke, B.; Goodwin, C.M.; Hobbs, G.A.; Diehl, J.N.; Yang, R.; Edwards, A.C.; Walsh, K.H.; Sulahian, R.; et al. Targeting p130cas- and microtubule-dependent myc regulation sensitizes pancreatic cancer to erk mapk inhibition. Cell Rep. 2021, 35, 109291. [Google Scholar] [CrossRef]
- Yaginuma, T.; Gao, J.; Nagata, K.; Muroya, R.; Fei, H.; Nagano, H.; Chishaki, S.; Matsubara, T.; Kokabu, S.; Matsuo, K.; et al. P130cas induces bone invasion by oral squamous cell carcinoma by regulating tumor epithelial-mesenchymal transition and cell proliferation. Carcinogenesis 2020, 41, 1038–1048. [Google Scholar] [CrossRef]
- Kumbrink, J.; Soni, S.; Laumbacher, B.; Loesch, B.; Kirsch, K.H. Identification of novel crk-associated substrate (p130cas) variants with functionally distinct focal adhesion kinase binding activities. J. Biol. Chem. 2015, 290, 12247–12255. [Google Scholar] [CrossRef] [Green Version]
- Van Slambrouck, S.; Grijelmo, C.; De Wever, O.; Bruyneel, E.; Emami, S.; Gespach, C.; Steelant, W.F. Activation of the fak-src molecular scaffolds and p130cas-jnk signaling cascades by alpha1-integrins during colon cancer cell invasion. Int. J. Oncol. 2007, 31, 1501–1508. [Google Scholar]
- Zhang, P.; Guo, A.; Possemato, A.; Wang, C.; Beard, L.; Carlin, C.; Markowitz, S.D.; Polakiewicz, R.D.; Wang, Z. Identification and functional characterization of p130cas as a substrate of protein tyrosine phosphatase nonreceptor 14. Oncogene 2013, 32, 2087–2095. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhao, Y.; Scott, A.; Zhang, P.; Hao, Y.; Feng, X.; Somasundaram, S.; Khalil, A.M.; Willis, J.; Wang, Z. Regulation of paxillin-p130-pi3k-akt signaling axis by src and ptprt impacts colon tumorigenesis. Oncotarget 2017, 8, 48782–48793. [Google Scholar] [CrossRef] [Green Version]
- Chen, L.; Long, X.; Duan, S.; Liu, X.; Chen, J.; Lan, J.; Liu, X.; Huang, W.; Geng, J.; Zhou, J. Csrp2 suppresses colorectal cancer progression via p130cas/rac1 axis-meditated erk, pak, and hippo signaling pathways. Theranostics 2020, 10, 11063–11079. [Google Scholar] [CrossRef] [PubMed]
- Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E.; et al. The cbio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2, 401–404. [Google Scholar] [CrossRef] [Green Version]
- Martinez-Jimenez, F.; Muinos, F.; Sentis, I.; Deu-Pons, J.; Reyes-Salazar, I.; Arnedo-Pac, C.; Mularoni, L.; Pich, O.; Bonet, J.; Kranas, H.; et al. A compendium of mutational cancer driver genes. Nat. Rev. Cancer 2020, 20, 555–572. [Google Scholar] [CrossRef]
- Hornbeck, P.V.; Zhang, B.; Murray, B.; Kornhauser, J.M.; Latham, V.; Skrzypek, E. Phosphositeplus, 2014: Mutations, ptms and recalibrations. Nucleic Acids Res. 2015, 43, D512–D520. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Elso, C.M.; Roberts, L.J.; Smyth, G.K.; Thomson, R.J.; Baldwin, T.M.; Foote, S.J.; Handman, E. Leishmaniasis host response loci (lmr1-3) modify disease severity through a th1/th2-independent pathway. Genes Immun. 2004, 5, 93–100. [Google Scholar] [CrossRef]
- Arnold, D.; Lueza, B.; Douillard, J.Y.; Peeters, M.; Lenz, H.J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J.P.; Tabernero, J.; et al. Prognostic and predictive value of primary tumour side in patients with ras wild-type metastatic colorectal cancer treated with chemotherapy and egfr directed antibodies in six randomized trials. Ann. Oncol. 2017, 28, 1713–1729. [Google Scholar] [CrossRef]
- Stintzing, S.; Ivanova, B.; Ricard, I.; Jung, A.; Kirchner, T.; Tannapfel, A.; Juette, H.; Hegewisch-Becker, S.; Arnold, D.; Reinacher-Schick, A. Amphiregulin (areg) and epiregulin (ereg) gene expression as predictor for overall survival (os) in oxaliplatin/fluoropyrimidine plus bevacizumab treated mcrc patients-analysis of the phase iii aio krk-0207 trial. Front. Oncol. 2018, 8, 474. [Google Scholar] [CrossRef]
- Stahler, A.; Heinemann, V.; Giessen-Jung, C.; Crispin, A.; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; et al. Influence of mrna expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-fu/lv plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (fire 1-trial). Int. J. Cancer 2016, 138, 739–746. [Google Scholar] [CrossRef] [Green Version]
- Kumbrink, J.; Kirsch, K.H. Regulation of p130(cas)/bcar1 expression in tamoxifen-sensitive and tamoxifen-resistant breast cancer cells by egr1 and nab2. Neoplasia 2012, 14, 108–120. [Google Scholar] [CrossRef] [Green Version]
- Ta, H.Q.; Thomas, K.S.; Schrecengost, R.S.; Bouton, A.H. A novel association between p130cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells. Cancer Res. 2008, 68, 8796–8804. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Van der Flier, S.; Brinkman, A.; Look, M.P.; Kok, E.M.; Meijer-van Gelder, M.E.; Klijn, J.G.; Dorssers, L.C.; Foekens, J.A. Bcar1/p130cas protein and primary breast cancer: Prognosis and response to tamoxifen treatment. J. Natl. Cancer Inst. 2000, 92, 120–127. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yeatman, T.J. A renaissance for src. Nat. Rev. Cancer 2004, 4, 470–480. [Google Scholar] [CrossRef] [PubMed]
- Kumbrink, J.; Kirsch, K.H. P130cas acts as survival factor during pma-induced apoptosis in hl-60 promyelocytic leukemia cells. Int. J. Biochem. Cell Biol. 2013, 45, 531–535. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, M.S.; McGuffey, E.J.; Morris, J.S.; Manyam, G.; Baladandayuthapani, V.; Wei, W.; Morris, V.K.; Overman, M.J.; Maru, D.M.; Jiang, Z.Q.; et al. Association of cpg island methylator phenotype and ereg/areg methylation and expression in colorectal cancer. Br. J. Cancer 2016, 114, 1352–1361. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, J.; Ma, X.; Chakravarti, D.; Shalapour, S.; DePinho, R.A. Genetic and biological hallmarks of colorectal cancer. Genes Dev. 2021, 35, 787–820. [Google Scholar] [CrossRef]
- Varghese, V.; Magnani, L.; Harada-Shoji, N.; Mauri, F.; Szydlo, R.M.; Yao, S.; Lam, E.W.; Kenny, L.M. Foxm1 modulates 5-fu resistance in colorectal cancer through regulating tyms expression. Sci. Rep. 2019, 9, 1505. [Google Scholar] [CrossRef] [Green Version]
- Ulrich, C.M.; Robien, K.; McLeod, H.L. Cancer pharmacogenetics: Polymorphisms, pathways and beyond. Nat. Rev. Cancer 2003, 3, 912–920. [Google Scholar] [CrossRef] [PubMed]
- Van Schaik, R.H. Cancer treatment and pharmacogenetics of cytochrome p450 enzymes. Investig. New Drugs 2005, 23, 513–522. [Google Scholar] [CrossRef]
- Clark, D.W.; Palle, K. Aldehyde dehydrogenases in cancer stem cells: Potential as therapeutic targets. Ann. Transl. Med. 2016, 4, 518. [Google Scholar] [CrossRef] [PubMed]
- Tikhmyanova, N.; Golemis, E.A. Nedd9 and bcar1 negatively regulate e-cadherin membrane localization, and promote e-cadherin degradation. PLoS ONE 2011, 6, e22102. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Beauchemin, N.; Arabzadeh, A. Carcinoembryonic antigen-related cell adhesion molecules (ceacams) in cancer progression and metastasis. Cancer Metastasis Rev. 2013, 32, 643–671. [Google Scholar] [CrossRef]
- Williams, C.J.M.; Seligmann, J.F.; Elliott, F.; Shires, M.; Richman, S.D.; Brown, S.; Zhang, L.; Singh, S.; Pugh, J.; Xu, X.M.; et al. Artificial intelligence-assisted amphiregulin and epiregulin ihc predicts panitumumab benefit in ras wild-type metastatic colorectal cancer. Clin. Cancer Res. 2021, 27, 3422–3431. [Google Scholar] [CrossRef]
- Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.; Pomeroy, S.L.; Golub, T.R.; Lander, E.S.; et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545–15550. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kumbrink, J.; Li, P.; Pók-Udvari, A.; Klauschen, F.; Kirchner, T.; Jung, A. p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy. Int. J. Mol. Sci. 2021, 22, 12364. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms222212364
Kumbrink J, Li P, Pók-Udvari A, Klauschen F, Kirchner T, Jung A. p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy. International Journal of Molecular Sciences. 2021; 22(22):12364. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms222212364
Chicago/Turabian StyleKumbrink, Jörg, Pan Li, Agnes Pók-Udvari, Frederick Klauschen, Thomas Kirchner, and Andreas Jung. 2021. "p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy" International Journal of Molecular Sciences 22, no. 22: 12364. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms222212364